Special Notice · 36C25027Q0091
Q301 - Notice of Intent to Sole-Source Veracyte Decipher Testing Services - Cleveland OH VAMC
Department of Veterans Affairs · Ohio
This is a notice (Special Notice), not a request for offers.
- Agency
- Department of Veterans Affairs Federal250-NETWORK Contract Office 10 (36C250)
- Place
- Ohio
- Offers due
- November 12, 2026, 4:00 PM (ET) closes in 3 days
- Estimated value
- not stated
- Notice type
- Special Notice
- Category
- Medical and pharmaceutical
- Product service code (PSC)
- Q301
- Posted
- November 4, 2026
- Solicitation number
- 36C25027Q0091
Opens the notice on SAM.gov, with its attachments and how to respond.
Source: SAM.gov Contract Opportunities, the U.S. government's official list of federal contract opportunities.
Description
Notice of Intent to Sole-Source Requirement The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The associated NAICS code for this is 334516, Size Standard is 1,000 employees. Product Service Code (PSC) is Q301. The sole-source contract will be awarded to: VERACYTE, INC UEI: JS7GBP6LCMN6 Description of equipment requirements: The VA Northeast Ohio Healthcare System (VANEOHS) requires continued access to specialized genomic classifier testing used to assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer. Decipher prostate testing is a powerful diagnostic and prognostic tool that assesses risk of prostate cancer progression within the next five years post detection, biopsy or surgical removal. The test utilizes a genome-wide transcriptome assay to analyze the expression of 22 genes to generate the Decipher score. Performed on existing tissue samples obtained during biopsy or surgical removal of the prostate, prior to any radiation or hormone therapy. Indicated in localized, N1, or metastatic disease. Provides the Decipher score based on genomic characteristics of the tumor, independent of clinical and pathological factors. The score, ranging between 0 and 1, reflects tumor aggressiveness. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government. The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government. All responses to this intent to sole source must be emailed to Thomas Bellamy: [email removed] & Samantha Jarrett: [email removed] by 4:00 p.m. EST November 12th, 2026.
Browse more bids
More open bids from this agency
- closes in 11 days
- closes in 4 days
- closes in 4 days
- closes in 3 days
- closes in 4 days
Similar open bids
- closes in 36 days
- closes in 36 days
- closes in 25 days
- closes in 11 days
- closes in 14 days
- closes in 28 days
- closes in 25 days
- closes in 3 days
- closes in 161 days
- closes in 4 days